- Home
- PRLD vs ELME Comparison
PRLD vs ELME Comparison
Compare PRLD & ELME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRLD | ELME |
|---|---|---|
| Founded | 2016 | 1960 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 218.0M | 198.2M |
| IPO Year | 2020 | 1994 |
Fundamental Metrics
Financial Performance| Metric | PRLD | ELME |
|---|---|---|
| Price | $4.30 | $2.04 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 4 |
| Target Price | $4.67 | ★ $12.67 |
| AVG Volume (30 Days) | 194.5K | ★ 1.4M |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 745.59% |
| EPS Growth | ★ 23.21 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $12,140,000.00 | ★ $206,360,000.00 |
| Revenue This Year | $320.10 | $5.03 |
| Revenue Next Year | $100.00 | $4.31 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 73.43 | N/A |
| 52 Week Low | $0.61 | $1.98 |
| 52 Week High | $4.19 | $17.68 |
Technical Indicators
Market Signals| Indicator | PRLD | ELME |
|---|---|---|
| Relative Strength Index (RSI) | 72.26 | 23.64 |
| Support Level | $1.02 | $1.99 |
| Resistance Level | N/A | $2.26 |
| Average True Range (ATR) | 0.36 | 0.05 |
| MACD | 0.06 | 0.07 |
| Stochastic Oscillator | 86.83 | 45.45 |
Price Performance
Historical ComparisonAbout PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.
About ELME Elme Communities
Elme Communities is a real estate investment trust engaged in owning and operating properties in the greater Washington DC metropolitan area. The company's real estate portfolio is comprised of office, retail, and multifamily properties located near transportation nodes. Washington REIT derives nearly all of its income in the form of rental revenue from tenants organized into long-term leases. The company's office assets contribute the majority of this income, while the rest is split fairly evenly between its retail and multifamily locations. Washington REIT's tenants are banking, consulting, law, and financial services firms.